Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (Dec 2018)

Posted by Matt Breese on Dec 7, 2018

Find me on:

According to our recent payer coverage analysis for cystic fibrosis (CF) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CF treatments shows that more than half of the covered lives under the pharmacy benefit in health exchange programs and Medicare formularies have some type of utilization management restriction.

MMIT-Reality Check-CF_4Q2018Data snapshot as of Q4 2018

Trends: Even with a host of medications to treat the condition, challenges to managing CF exist, including the high cost of care, drug burden and having to get multiple medicines from more than one pharmacy. Via AIS Health.

To read the full Reality Check on Cystic Fibrosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


                                                      View Reality Check


Topics: Specialty, Market Access, Payer, Branding & Marketing